[Report] Global Nucleic Acid-Based Therapeutics Developments & Applications Market Research, Trends, Analysis TOC

Chapter One: Executive Summary

Background
Scope and Methodology
Market Size and Growth
Industry Structure
Key Strategic Trends

Chapter Two: Therapeutic Nucleic Acid Technologies

Ribonucleic Acid Inhibition (RNAi)
Gene Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Triplex Antisense

Chapter Three: Applications of Nucleic Acid-Based Therapeutics

Cancer
Rheumatoid Arthritis
Diabetes
Cardiovascular Diseases
Hypertension
Coronary Artery Disease (CAD)
Congestive Heart Failure (CHF)
Autoimmune Diseases
Neurological Diseases
Peripheral Nerve and Skeletal Muscle Diseases and Disorders
Central Nervous System Diseases and Disorders
Viral Infections
Miscellaneous Applications

Chapter Four: The Markets for Nucleic Acid-Based Therapeutics

Background
Disease Applications
Cancer
Rheumatoid Arthritis
Diabetes
Cardiovascular Disease
Autoimmune Diseases
Neurological Diseases
Viral Diseases
Miscellaneous Conditions
The Seven Major World Markets
United States
Japan
Germany
France
United Kingdom
Italy
Spain
Chapter Five: Company Profiles
Alnylam Pharmaceuticals
Amaxa Biosystems GmbH
Antisense Therapeutics Ltd.
Ark Therapeutics Group Plc.
Atugen
BioVex Ltd.
Cell Genesys
Cenix BioScience, GmbH
Ceregene Inc.
Collateral Therapeutics, Inc. (Division of Schering AG)
Copernicus Therapeutics, Inc.
Crucell NV
Dharmacon, Inc. (Subsidiary of Fisher Scientific)
ExpressOn Biosystems Ltd.
Galapagos Genomics
Genta Inc.
Genteric, Inc.
GenVec, Inc.
Gilead Sciences
Hybridon
Introgen Therapeutics, Inc.
Isis Pharmaceuticals, Inc.
Mirus Bio Corporation
Oxford BioMedica
Selective Genetics
Sirna Therapeutics
Targeted Genetics
Transgene
Valentis
Vectron Therapeutics AG
Chapter Six: Conclusions and Strategic Implications

Appendix A: Glossary

Appendix B: Company Names and Addresses

List of Tables
- Table 1-1: Market Potential for Nucleic Acid-Based Therapeutics in the Global Healthcare Markets by Application: 2004 - 2014
- Table 1-2: Market Potential for Nucleic Acid-Based Therapeutics in the Seven Major World Healthcare Markets by Application: 2004 - 2014
- Table 3-1: Estimated Incidence of Cancer in the Major World Healthcare Markets (Millions of Cases)
- Table 3-2: Age Distribution for the Populations of the Seven Major World Healthcare Markets: 2004
- Table 3-3 : Therapeutic Options in the Treatment of Cancer
- Table 3-4: Key Nucleic Acid-Based Cancer Therapeutics in Development
- Table 3-5: Prevalence of Rheumatoid Arthritis Cases in the United States for the Total Population and Those 45 Years of Age and Older: 2004 - 2014
- Table 3-6: Prevalence of Rheumatoid Arthritis in the Major World Healthcare Markets (Millions of Cases)
- Table 3-7: Key Nucleic Acid-Based Rheumatoid Arthritis Therapeutics in Development
- Table 3-8: Characteristics of Type 1 and Type 2 Diabetes Mellitus
- Table 3-9: Key Nucleic Acid-Based Diabetes Therapeutics in Development
- Table 3-10: Prevalence of Diagnosed Diabetes (Type I vs Type II) in the Major World Healthcare Markets 2004-2014
- Table 3-11: Prevalence of Cardiovascular Diseases by Type (Hypertension, CAD, CHF) in the Major World Healthcare Markets 2004-2014
- Table 3-12: Therapeutic Strategies for Symptomatic Congestive Heart Failure
- Table 3-13: Pharmacological Response to the Pathophysiology of Cardiac Performance
- Table 3-14: Key Nucleic Acid-Based Cardiovascular Therapeutics in Development
- Table 3-15: Recognized Autoimmune Diseases
- Table 3-16: Prevalence of Autoimmune Diseases by Type (Psoriasis, Lupus Erythematosus, Psoriatic Arthritis, Scleroderma) in the Major World Healthcare Markets 2004-2014
- Table 3-17: Neurological Diseases and Disorders as Classified by the United States National Institute of Neurological Disorders and Stroke (NINDS): 2002
- Table 3-18: Classification of Diseases and Disorders of Peripheral Nerve and Skeletal Muscle
- Table 3-19: Classification of Diseases and Disorders of the Central Nervous System
- Table 3-20: Prevalence of Neurological Diseases by Type (Peripheral Neuropathies, Alzheimers Disease, Epilepsy, Parkinsons Disease, MS, Severe Traumatic Brain Injury, Spinal Cord Injury) in the Major World Healthcare Markets 2004-2014
- Table 3-21: Key Nucleic Acid-Based Neurological Therapeutics in Development
- Table 3-22: Key Nucleic Acid-Based Viral Therapeutics and Vaccines in Development
- Table 3-23: Prevalence of Key Viral Diseases by Type (CMV, HSV, HPV, HCV, HIV, HBV, WNV) in the Major World Healthcare Markets 2004-2014
- Table 3-24: Key Nucleic Acid-Based Therapeutics and Vaccines in Development for Miscellaneous Applications
- Table 4-1: Populations of the Seven Major World Healthcare Markets 2004-2014
- Table 4-2: Cancer Markets in the Seven Major World Healthcare Markets by Country: 2004-2014
- Table 4-3: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Cancer in the Seven Major World Healthcare Markets by Country 2004 - 2014
- Table 4-4: Rheumatoid Arthritis Markets in the Seven Major World Healthcare Markets by Country 2004 - 2014
- Table 4-5: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Rheumatoid Arthritis in the Seven Major World Healthcare Markets by Country: 2004 - 2014
- Table 4-6: Diabetes Markets in the Seven Major World Healthcare Markets by Country and Type (Insulin vs Oral Hypoglycemics) 2004 - 2014
- Table 4-7: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Diabetes in the Seven Major World Healthcare Markets by Country 2004 - 2014
- Table 4-8: Cardiovascular Disease Markets in the Seven Major World Healthcare Markets by Countryand Type (Hypertension, CAD, CHF) 2004 - 2014
- Table 4-9: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Cardiovascular Disease in the Seven Major World Healthcare Markets by Country and Type (Hypertension, CAD, CHF) 2004 - 2014
- Table 4-10: Autoimmune Disease Markets in the Seven Major World Healthcare Markets by Country and Type (Psoriasis, Lupus Erythematosus, Psoriatic Arthritis, Scleroderma) 2004 - 2014
- Table 4-11: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Autoimmune Diseases in the Seven Major World Healthcare Markets by Country and Type (Psoriasis, Lupus Erythematosus, Psoriatic Arthritis, Scleroderma) 2004 - 2014
- Table 4-12: Neurological Disease Markets in the Seven Major World Healthcare Markets by Country and Type (Peripheral Neuropathies, Alzheimers Disease, Epilepsy, Parkinsons Disease, MS, Severe Traumatic Brain Injury, Spinal Cord Injury) 2004 - 2014
- Table 4-13: Market Potential for Nucleic Acid-Based Therapeutics for the Treatment of Neurological Diseases in the Seven Major World Healthcare Markets by Country and Type (Peripheral Neuropathies, Alzheimers Disease, Epilepsy, Parkinsons Disease, MS, Severe Traumatic Brain Injury, Spinal Cord Injury) 2004 - 2014
- Table 4-14: Market Potential for Nucleic Acid-Based Therapeutics in the Global Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-15: Market Potential for Nucleic Acid-Based Therapeutics in the Seven Major World Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-16: Market Potential for Nucleic Acid-Based Therapeutics in the United States Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-17: Market Potential for Nucleic Acid-Based Therapeutics in the Japanese Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-18: Market Potential for Nucleic Acid-Based Therapeutics in the German Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-19: Market Potential for Nucleic Acid-Based Therapeutics in the French Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-20: Market Potential for Nucleic Acid-Based Therapeutics in the United Kingdoms Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-21: Market Potential for Nucleic Acid-Based Therapeutics in the Italian Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
- Table 4-22: Market Potential for Nucleic Acid-Based Therapeutics in the Spanish Healthcare Markets by Disease Area (Cancer, Rheumatoid Arthritis, Diabetes, Cardiovascular Disease, Autoimmune Disease, Neurological Disease) 2004 - 2014
List of Figures
- Figure 1-1: Composition by Disease Area of the Market Potential for Nucleic Acid Therapeutics in the Global Healthcare Markets: 2004
- Figure 2-1: The General Shape of Short Hairpin RNAs (shRNAs)
- Figure 2-2: The Purine Bases of Nucleic Acid Structure
- Figure 2-3: The Pyrimidine Bases of Nucleic Acid Structure
- Figure 2-4: 23-Dideoxynucleoside Analogs
- Figure 2-5: Structures of Allopurinol and Hypoxanthine
- Figure 2-6: Structures of Methotrexate and Trimethoprim
- Figure 2-7: Structure of 5-Iododeoxyuridine
- Figure 2-8: Structure of Acyclovir
- Figure 2-9: Structure of Ganciclovir
- Figure 2-10: Structure of Arabinosyladenine
- Figure 2-11: Structure of Arabinosylcytosine
- Figure 2-12: Structure of 3-Azido-23-Dideoxythymidine (AZT)
- Figure 2-13: Structure of 2,3-Dideoxycytidine (ddC)
- Figure 2-14: Structure of 2,3-Dideoxyinosine (ddI)
- Figure 2-15: Structure of Metallotexaphyrin
- Figure 3-1: Distribution of Cancer Incidence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-2: Trending in United States Rheumatoid Arthritis Cases in the 45+ Year Old Age Group: 2003 - 2013
- Figure 3-3: Distribution of Rheumatoid Arthritis Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-4: Distribution of Type I Diabetes Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-5: Distribution of Type II Diabetes Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-6: Distribution of All Diabetes Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-7: Distribution of Hypertension Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-8: Distribution of Coronary Artery Disease (CAD) Prevalence by Major Healthcare Market: 2004, 2009, 2014:
- Figure 3-9: Distribution of Congestive Heart Failure (CHF) Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-10: Distribution of All Cardiovascular Disease (CVD) Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-11: Distribution of Psoriasis Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-12: Distribution of Lupus Erythematosus Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-13: Distribution of Psoriatic Arthritis Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-14: Distribution of All Scleroderma Prevalence by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-15: Distribution of All Selected Autoimmune Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-16: Structure of the Normal Motor Neuron
- Figure 3-17: Distribution of Peripheral Neuropathy Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-18: Distribution of Alzheimers Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-19: Distribution of Epilepsy Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-20: Distribution of Parkinsons Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-21: Distribution of Multiple Sclerosis Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-22: Distribution of Severe Brain Injury Incidences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-23: Distribution of Spinal Cord Injury Incidences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-24: Distribution of All Selected Neurological Disease Prevalences by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-25: Distribution of Cytomegalovirus (CMV) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-26: Distribution of Herpes Simplex Virus (HSV-1/HSV-2) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-27: Distribution of Human Papilloma Virus (HPV) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-28: Distribution of Hepatitis C Virus (HCV) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-29: Distribution of Human Immunodeficiency Virus (HIV) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-30: Distribution of Hepatitis B Virus (HBV) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-31: Distribution of West Nile Virus (WNV) Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 3-32: Distribution of All Selected Viral Infections by Major Healthcare Market: 2004, 2009, 2014
- Figure 4-1: Distribution of the Replacement Market Potential for Nucleic Acid-Based Cancer Therapeutics in Each of the Seven Major World Healthcare Markets
- Figure 4-2: Percentage Composition of the Market Potential For Nucleic Acid-Based Cancer Therapeutics Among The Seven Major World Healthcare Markets
- Figure 4-3: Distribution of the Replacement Market Potential for Nucleic Acid-Based Rheumatoid Arthritis Therapeutics in Each of the Seven Major World Healthcare Markets
- Figure 4-4: Percentage Composition of the Market Potential For Nucleic Acid-Based Rheumatoid Arthritis Therapeutics Among The Seven Major World Healthcare Markets
- Figure 4-5: Distribution of the Replacement Market Potential for Nucleic Acid-Based Diabetes Therapeutics in Each of the Seven Major World Healthcare Markets
- Figure 4-6: Percentage Composition of the Market Potential for Nucleic Acid-Based Diabetes Therapeutics Among the Seven Major World Healthcare Markets
- Figure 4-7: Distribution of the Replacement Market Potential for Nucleic Acid-Based Cardiovascular Disease Therapeutics in Each of the Seven Major World Healthcare Markets
- Figure 4-8: Percentage Composition of The Market Potential For Nucleic Acid-Based Cardiovascular Disease Therapeutics Among the Seven Major World Healthcare Markets
- Figure 4-9: Distribution of the Replacement Market Potential for Nucleic Acid-Based Autoimmune Disease Therapeutics in Each of the Seven Major World Healthcare Markets
- Figure 4-10: Percentage Composition of The Market Potential For Nucleic Acid-Based Cardiovascular Disease Therapeutics Among The Seven Major World Healthcare Markets
- Figure 4-11: Distribution of the Replacement Market Potential for Nucleic Acid-Based Neurological Disease Therapeutics in Each of the Seven Major World Healthcare Markets
- Figure 4-12: Percentage Composition of The Market Potential For Nucleic Acid-Based Neurological Disease Therapeutics Among The Seven Major World Healthcare Markets Figure 4-13: Composition of the Market Potential for Nucleic Acid Therapeutics in the Global Healthcare Markets: 2004
- Figure 4-14: Composition of the Market Potential for Nucleic Acid Therapeutics in the Seven Major World Healthcare Markets: 2004
- Figure 4-15: Composition of the Market Potential for Nucleic Acid Therapeutics in the United States Healthcare Markets: 2004
- Figure 4-16: Composition of the Market Potential for Nucleic Acid Therapeutics in the Japanese Healthcare Markets: 2004
- Figure 4-17: Composition of the Market Potential for Nucleic Acid Therapeutics in the German Healthcare Markets: 2004
- Figure 4-18: Composition of the Market Potential for Nucleic Acid Therapeutics in the French Healthcare Markets: 2004
- Figure 4-19: Composition of the Market Potential for Nucleic Acid Therapeutics in the United Kingdoms Healthcare Markets: 2004
- Figure 4-20: Composition of the Market Potential for Nucleic Acid Therapeutics in the Italian Healthcare Markets: 2004
- Figure 4-21: Composition of the Market Potential for Nucleic Acid Therapeutics in the Spanish Healthcare Markets: 2004:

Nucleic Acid-Based Therapeutics: World Markets, Developments, and Applications